LYEL Lyell: Enterprise Value-to-Revenue Multiple

Public company logo of lyell.com (LYEL)

Lyell Immunopharma focuses on reprogramming T-cells to combat solid tumors. The specifics of the R&D sector render the company independent of economic cycles. The price-to-sales multiple trend clearly captures the market valuation of the business, where 20645000.00 describes the current status of the metric. Leadership in creating exhaustion-resistant biomedical platforms provides the firm with powerful scientific potential.

Company Value to Revenue: Lyell (LYEL) for 11/23/2025 - 11/21/2026

lyell.com - analytical breakdowns and key metrics (LYEL)

- share price and consensus valuation forecast:
Initial company analysis:Lyell Immunopharma LYEL
Product sample of Lyell Immunopharma

Lyell Immunopharma's in-house manufacturing capabilities reduce operating expenses, which directly impacts revenue generation efficiency. The EV/Sales metric measures the total value of the business, including debt and cash, per unit of sales. By analyzing the EV/Sales multiple trajectory, an investor can see the market valuation of the asset stripped of leverage influence. The price action of the curve confirms the objectivity of the capitalization relative to actual cash flows, allowing for an assessment of the company's resilience to market volatility.

Competitor analysis for Lyell Immunopharma

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP